Olabir Tablets — Olaparib 150 mg (120 Tablets) Aprazer

Olabir is prescribed by an oncologist (as monotherapy or in combination therapy) for patients with specific genetic markers:

• 🔹 Ovarian cancer (including fallopian tube or primary peritoneal cancer) — maintenance treatment following chemotherapy.
• 🔹 Breast cancer (metastatic, HER2-negative, with germline BRCA mutation).
• 🔹 Prostate cancer (metastatic castration-resistant prostate cancer with HRR gene mutations).
• 🔹 Pancreatic adenocarcinoma (metastatic, with germline BRCA mutation).

Sales Unit: 1 pack containing 120 tablets, each with 150 mg of Olaparib.

⚠️ APPLICATION INSTRUCTIONS:

• Dosage: The standard recommended dose is 300 mg (two 150 mg tablets) taken twice daily (total daily dose of 600 mg).
• Method: Swallow tablets whole. May be taken with or without food.
• Duration: Treatment continues until disease progression or unacceptable toxicity occurs.
• Storage: Store in the original package below 30°C in a dry place.

• ⛔ Pregnancy and Breastfeeding: Olaparib is highly hazardous to the fetus. It is strictly contraindicated during pregnancy and lactation.
• ⛔ Renal Impairment: Severe renal impairment or end-stage renal disease requiring dialysis.
• Hypersensitivity to Olaparib or any of its excipients.
• Pediatric use (safety and efficacy in children under 18 have not been established).

Treatment requires regular medical supervision. Potential side effects include:

• 🩸 Hematologic: Anemia, neutropenia, and leukopenia.
• 🤢 Gastrointestinal: Nausea, vomiting, diarrhea, and decreased appetite.
• 🏃‍♂️ General: Fatigue (asthenia), dizziness, and taste disturbances (dysgeusia).
• 🩺 Lab findings: Increased blood creatinine levels.